Ask the Expert: Do Low Volume Metastatic Disease Patients Benefit from Early Docetaxal?

Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC, University of Oklahoma College of Medicine, Norman, Oklahoma, discusses whether hormone sensitive, newly diagnosed metastatic prostate cancer patients should receive chemotherapy and androgen deprivation therapy.

Interview produced by Prostatepedia

Keywords: Metastatic Prostate Cancer, Chemotherapy, Androgen Deprivation Therapy, STAMPEDE, CHARTERED, French Study

ABOUT THE AUTHOR

Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology residency at the University of Texas, San Antonio, and completed his Urologic Oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University in Nashville, Tennessee.

About The Author

Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology residency at the University of Texas, San Antonio, and completed his Urologic Oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University in Nashville, Tennessee. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidence-based medicine. He was a member of the AUA/ABU Examination Committee for 10 years, serving as Oncology Consultant and Pathology Editor. He also serves on the ABU Oral Examination Committee. He is a Co-Founder of the Oncology Knowledge Assessment Test (OKAT), an SUO-mandated examination. He also served as Chair for the OKAT for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He received the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as Chair of the Castration-Resistant Prostate Cancer Guidelines Committee at the AUA 2018 Annual Meeting. Dr. Cookson has previously served as a member of the AUA Guidelines on Localized Prostate Cancer Committee. Dr. Cookson is currently serving out the 2019-2020 term as the SUO President.

Share This

Chat with usLiveChat